Marijuana Schedule III Status Temporarily Secured Amid Legal Challenges

In a legal setback for the marijuana industry, the United States Court of Appeals for the District of Columbia Circuit has denied a request to suspend the federal government's limited Schedule III order for marijuana. The order, issued in April 2026, placed marijuana contained in FDA-approved drug products and marijuana subject to qualifying state medical-marijuana licenses into Schedule III. This decision allows the existing order to remain in effect during judicial review but does not address the legality of the order or resolve the broader DEA proceeding considering a more comprehensive rescheduling.

Duane Boise, President of MMJ International Holdings, expressed, "The court decided whether the extraordinary remedy of an interim stay was warranted before full merits briefing. It did not decide whether the Attorney General had authority to create this unprecedented Schedule III system without completing the procedures Congress enacted."

MMJ International Holdings, along with other petitioners, is challenging the federal rescheduling action. The consolidated litigation, SAM, Inc. v. United States Department of Justice, has been ongoing, and the court's two-page order explicitly stated that the petitioners had not satisfied the "stringent requirements" for a stay pending review. The court did not identify the specific basis for its decision, leaving open questions about the legality of the order.

Boise further elaborated, "This was not the finish line. The central statutory questions remain unanswered." The court's decision does not address whether MMJ or other petitioners have Article III standing, whether the Attorney General exceeded his authority under 21 U.S.C. § 811(d), or whether the Single Convention on Narcotic Drugs required the specific two-category order. The court also did not rule on whether the government unlawfully relied on state licensing to confer Schedule III treatment or whether DEA effectively amended registration requirements without notice and comment.

The order continues to have significant implications for the industry. MMJ BioPharma Cultivation, Inc. and MMJ BioPharma Labs, Inc., affiliates of MMJ International Holdings, are among the entities that remain subject to the Schedule III status, potentially benefiting from the reduced regulatory burden. However, MMJ maintains that the order is unlawful, as it treats FDA pathway cannabinoid medicines differently from state-licensed medical marijuana, alleging unequal treatment and competitive injury.

The financial benefits of the Schedule III status remain exposed to judicial review. Covered state medical-marijuana operators may continue operating under the order while the appeal proceeds, including any applicable consequences under Internal Revenue Code Section 280E. However, the industry is uncertain about the long-term legal and financial consequences of the order, as the D.C. Circuit has not yet decided the merits of the consolidated appeals.

A separate DEA administrative proceeding is considering a broader question: whether marijuana generally should be transferred from Schedule I to Schedule III. The DEA has argued that marijuana no longer satisfies the statutory requirements for Schedule I, citing more than 30,000 practitioners treating over six million patients in 43 jurisdictions as evidence of accepted medical use and accepted safety under medical supervision. MMJ disputes these claims, asserting that state authorization and physician certification do not equate to FDA approval or prescription for an approved pharmaceutical.

Boise emphasized, "Widespread use may be evidence for the government to evaluate, but volume alone does not transform variable products into scientifically validated medicines." The outcome of both the court case and the DEA proceeding will have far-reaching implications for the marijuana industry, potentially reshaping its regulatory landscape and business operations.

In conclusion, while the limited Schedule III order for marijuana remains in effect, the legal and regulatory battles continue, leaving the industry in a state of uncertainty.